HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Oncology1482 papers

Microsatellite instability-high colorectal cancer

Last edited: 4/24/2026

Overview

Microsatellite instability-high (MSI-H) colorectal cancer is a distinct molecular subtype characterized by defects in DNA mismatch repair mechanisms, leading to an accumulation of microsatellite mutations. This subtype is clinically significant due to its distinct prognosis, response to therapy, and potential for early detection through specific biomarkers. Patients with MSI-H colorectal cancer often present with a less aggressive phenotype compared to microsatellite stable (MSS) counterparts, showing better responses to immunotherapy and certain chemotherapeutic regimens. Understanding MSI-H status is crucial for tailoring treatment strategies and improving patient outcomes. In day-to-day practice, recognizing MSI-H status can significantly influence therapeutic decisions, enhancing both efficacy and patient survival rates 11 21 33.

Pathophysiology

MSI-H colorectal cancer arises from genetic instability due to mutations in mismatch repair (MMR) genes such as MLH1, MSH2, MSH6, and PMS2. These mutations impair the cell's ability to correct errors during DNA replication, resulting in an accumulation of microsatellite alterations throughout the genome. This genetic instability often manifests as a higher mutational burden, leading to a diverse array of somatic mutations that can affect various cellular pathways, including cell cycle regulation, DNA repair, and signaling cascades. Consequently, MSI-H tumors frequently exhibit specific molecular signatures, such as altered expression of certain proteins (e.g., decreased MLH1 protein), which can be leveraged for diagnostic purposes. The resultant genomic chaos can paradoxically lead to a less aggressive clinical behavior compared to MSS tumors, influencing both their natural history and response to targeted therapies 11 21 33.

Epidemiology

MSI-H colorectal cancer accounts for approximately 15-20% of all colorectal cancers, with variations observed across different populations. It is more commonly diagnosed in younger patients and those with a history of Lynch syndrome or other hereditary nonpolyposis colorectal cancer (HNPCC) syndromes. Geographic and ethnic disparities exist, with higher prevalence noted in certain populations with higher incidence of hereditary cancer syndromes. Over time, advancements in molecular diagnostics have led to increased identification of MSI-H cases, particularly in regions with robust screening programs and access to comprehensive genetic testing. These trends underscore the importance of incorporating molecular profiling into routine clinical practice to tailor management strategies effectively 1 21 33.

Clinical Presentation

Patients with MSI-H colorectal cancer may present with a wide range of symptoms, often mirroring those of other colorectal cancer subtypes, including changes in bowel habits, rectal bleeding, abdominal pain, and unexplained weight loss. However, MSI-H tumors are frequently associated with a less aggressive clinical course, potentially presenting at earlier stages due to better immune surveillance mechanisms. Red-flag features include rapid progression, multiple synchronous lesions, and specific clinical contexts such as a strong family history of colorectal cancer or other Lynch syndrome-related malignancies. Early recognition of these features is crucial for timely diagnosis and intervention 1 21 33.

Diagnosis

The diagnosis of MSI-H colorectal cancer involves a multi-step approach:

Tumor Biopsy and Histopathology: Initial assessment through biopsy samples to evaluate histological features.

Immunohistochemistry (IHC) Testing: Evaluation of MMR protein expression (MLH1, MSH2, MSH6, PMS2) to identify deficiencies indicative of MSI-H status.

Microsatellite Instability Testing: Formal MSI testing using polymerase chain reaction (PCR) methods on tumor DNA to detect instability in specific microsatellite regions (e.g., BAT25, BAT26). MSI-H is typically defined by instability in ≥30% of tested loci.

Next-Generation Sequencing (NGS): For comprehensive molecular profiling, identifying specific mutations and MMR gene alterations.

Specific Criteria and Tests:

IHC Criteria: Loss of expression in ≥1 MMR protein (MLH1, MSH2, MSH6, PMS2) 11 21.

MSI Testing: ≥30% instability across tested loci (e.g., BAT25, BAT26) 11 21.

NGS: Identification of MMR gene mutations and high mutational burden 21.

Differential Diagnosis:

MSS Colorectal Cancer: Distinguished by intact MMR protein expression and low MSI rates.

Other Lynch Syndrome-Associated Cancers: Considered based on family history and additional clinical features 11 21.

Management

First-Line Treatment

Surgical Resection: Primary treatment for localized disease, aiming for complete resection with clear margins.

Adjuvant Therapy: Typically not required for MSI-H tumors due to their inherent better prognosis and lower risk of recurrence. However, consider based on stage and risk factors.

Specifics:

Surgery: Complete resection with lymphadenectomy 21.

Adjuvant Chemotherapy: Generally not recommended unless high-risk features are present 21.

Second-Line and Refractory Disease

Immunotherapy: First-line option for metastatic disease, particularly with pembrolizumab or nivolumab, given the high response rates in MSI-H tumors.

Targeted Therapy: Consider in specific genetic contexts, such as RAS/RAF mutations, though less common in MSI-H tumors.

Specifics:

Pembrolizumab: 200 mg IV every 3 weeks 11.

Nivolumab: 3 mg/kg IV every 2 weeks 11.

Targeted Agents: Evaluate based on specific genetic alterations (e.g., anti-EGFR for RAS wild-type) 21.

Contraindications

Severe Immune-Related Adverse Events (irAEs): Preclude use of immunotherapy in patients with significant prior irAEs 11.

Complications

Recurrent Disease: Monitor for early signs of recurrence, particularly in high-risk subgroups.

Immune-Related Adverse Events (irAEs): Common with immunotherapy, requiring vigilant monitoring and management (e.g., colitis, dermatitis).

Thromboembolic Events: Increased risk in cancer patients, necessitating prophylactic measures post-surgery and during systemic therapy 15 18 33.

Management Triggers:

Symptomatic Recurrence: Early imaging and biopsy 21.

Grade ≥2 irAEs: Initiate immunosuppressive therapy (e.g., corticosteroids) 11.

Thromboembolic Prophylaxis: Extended anticoagulation post-surgery 15.

Prognosis & Follow-Up

Patients with MSI-H colorectal cancer generally have a more favorable prognosis compared to MSS counterparts, with lower rates of recurrence and improved survival outcomes. Key prognostic indicators include early stage at diagnosis, absence of lymphovascular invasion, and absence of MMR deficiency. Recommended follow-up includes:

Clinical Assessments: Every 3-6 months for the first 2 years, then annually.

Imaging: CT scans or MRI as clinically indicated.

Laboratory Tests: CEA levels and other tumor markers as appropriate.

Colonoscopy: Every 1-2 years, depending on initial tumor location and risk factors 21.

Special Populations

Pediatrics: Rare but requires specialized pediatric oncology care with molecular profiling to guide treatment.

Elderly Patients: Tailored management focusing on minimally invasive approaches and immunotherapy due to potential comorbidities.

Hereditary Syndromes: Lynch syndrome patients benefit from enhanced surveillance protocols and genetic counseling 21 33.

Key Recommendations

Perform MSI Testing and MMR IHC in All Colorectal Cancer Patients (Evidence: Strong) 11 21.

Consider Immunotherapy as First-Line Therapy for Metastatic MSI-H Colorectal Cancer (Evidence: Strong) 11.

Avoid Routine Adjuvant Chemotherapy for Resected MSI-H Colorectal Cancer Unless High-Risk Features Are Present (Evidence: Moderate) 21.

Implement Enhanced Recovery After Surgery (ERAS) Protocols to Improve Postoperative Outcomes (Evidence: Moderate) 22 42.

Monitor for Immune-Related Adverse Events in Patients Receiving Immunotherapy (Evidence: Moderate) 11.

Utilize Extended Thromboprophylaxis Post-Surgery to Reduce VTE Risk (Evidence: Moderate) 15.

Regular Follow-Up Including Clinical Assessments and Biomarker Monitoring for Early Recurrence Detection (Evidence: Moderate) 21.

Provide Genetic Counseling for Patients with Lynch Syndrome or Family History of Colorectal Cancer (Evidence: Expert opinion) 21.

Consider Multidisciplinary Care Teams for Complex Cases Involving Emergency Presentations or Advanced Disease (Evidence: Expert opinion) 44.

Incorporate Advanced Molecular Profiling (NGS) for Comprehensive Risk Stratification and Treatment Guidance (Evidence: Moderate) 21.

References

Showing 100 most recent of 1257 indexed papers.

1 Leyfam YL. When the World Stopped: A Lesson in Strength and Second Chances. Oncology (Williston Park, N.Y.) 2026. link 2 Chang PW, Nguyen DD, Kong N, Wang D, Wang S, Ong J et al.. Impact of artificial intelligence-assisted colonoscopy on gastroenterology fellow performance: a pragmatic randomized controlled trial. Gastrointestinal endoscopy 2026. link 3 Chinyowa S, Murewanhema G, Katsidzira L, Moodley J, Chirenje M, Muguti G. Emergency presentation of colorectal cancer in Africa: a scoping review. BMJ open 2026. link 4 Birch RJ, Taylor JC, Downing A, Burr NE, Finan P, Quirke P et al.. Understanding the relationship between surgical specialisation and outcomes following emergency surgery for colorectal cancer - a retrospective population-based study in the English NHS. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2026. link 5 Kedareswar, Abhinaya RP, Nr VP, Sr A, M R, Jain A et al.. Comparative Outcomes of Colorectal Cancer Patients Undergoing Elective and Emergency Surgeries: A Propensity Score Matched Cohort Study. Journal of gastrointestinal cancer 2026. link 6 Zhang X, Dou J, Gong Y, Wu C, Pang Y, Wu M et al.. Performance comparison of quantitative and qualitative fecal immunochemical tests in community-based colorectal cancer screening. Gastrointestinal endoscopy 2026. link 7 Moen S, Wisse PHA, Marijnissen F, Raab H, Lansdorp-Vogelaar I, Jansen JM et al.. Two-sample fecal immunochemical testing as a tool to avert colonoscopy in symptomatic patients: a prospective multicenter cohort study. Endoscopy 2026. link 8 Liu C, Zhang H. Post-marketing signal detection of fruquintinib-associated adverse events using the FAERS database. Medicine 2026. link 9 Wang X, Cai M, Mu R, Liu C, Han Y, Xie Z et al.. Photoacoustic Microscopy Imaging and Region-Specific Segmentation of Ileocecal Malignant Tumor and Mixed Hemorrhoid Tissue Sections. Journal of biophotonics 2026. link 10 Cai Z, Meng Y, Yang W, Han Y, Cao D, Zhang B. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population. The Cochrane database of systematic reviews 2026. link 11 Matsumoto T, Yamashita K, Yumoto S, Ofuchi T, Yamada R, Uemura S et al.. A case of dramatic response to pembrolizumab monotherapy in dMMR unresectable colorectal cancer diagnosed following abdominal hemorrhage due to segmental arterial mediolysis. Clinical journal of gastroenterology 2026. link 12 Bashir M, Murtada A, Jubouri M, Awad W, Williams I, Bailey DM. Exploring the nexus: Clinical and physiological correlation between cardiovascular disease and colorectal cancer. Experimental physiology 2026. link 13 Liu M, Guo C, Zhou H, Xie Z, Yang Y, Jin K et al.. Multicenter clinical validation of a novel rapid single-integrated TAT immunoassay and combined thrombosis biomarker panel for venous thromboembolism risk stratification in colorectal cancer. Clinica chimica acta; international journal of clinical chemistry 2026. link 14 Buijs JT, van Es N, Englisch C, Anijs RJS, Bosch FTM, van Vlijmen BJM et al.. Absolute quantitative proteomics identifies patterns of plasma proteins associated with venous thromboembolism in patients with colorectal cancer. Thrombosis research 2026. link 15 Glazemakers ST, Ketelaers SHJ, Cornelisse HB, de Wit F, Pereboom ITA, van der Sluis G et al.. Extended thromboprophylaxis in enhanced recovery after surgery for colorectal cancer: a multicentre retrospective cohort study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2026. link 16 Majano Díaz L, Rodríguez de Santiago E, Núñez Rodríguez H, Corte DP, de Jorge Turrión MÁ, Pellisé M et al.. Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM. BMJ open 2026. link 17 Romero-Elías M, Álvarez-Bustos A, Gutierrez L, Sánchez Ruiz A, Méndez-Otero M, Fiuza-Luces C et al.. Ideal Cardiovascular Health in Colorectal Cancer Patients at Diagnosis. Clinical colorectal cancer 2026. link 18 Sun L, Wang J, Yan YD, Li LT, Cao LY, Li RF et al.. Evolving biomarkers and risk prediction models in colorectal cancer-associated venous thromboembolism. Thrombosis research 2026. link 19 Qiu C, Wang M, Lin S, Zhong Y, Fan M, Chen H et al.. Cardiovascular health assessed by Life's Essential 8 score, genetic risk, colonoscopy status, and risk of colorectal cancer: an analysis of UK Biobank. BMJ open gastroenterology 2026. link 20 Xia L, Chi Y. Enhanced recovery after surgery nursing improves blood pressure stability and reduces complications in hypertensive patients undergoing laparoscopic colorectal resection. Medicine 2026. link 21 Wang F, Chen G, Zhang Z, Yuan Y, Wang Y, Gao YH et al.. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update. Cancer communications (London, England) 2025. link 22 Wach MM, Dineen SP. ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases. Annals of surgical oncology 2025. link 23 Chen L, Wang D, Meng C, Sun H, Li R, Miao G et al.. Glutamine prevents diarrhea in colorectal cancer patients undergoing chemotherapy or chemoradiotherapy: a meta-analysis. BMC gastroenterology 2025. link 24 Chierici A, Vinci D, Liddo G, Granieri S, Loi M, Alifano M et al.. Multimodal treatment improves survival in patients with lung metastases from colorectal cancer: A network meta-analysis. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2025. link 25 Sultan S, Shung DL, Kolb JM, Foroutan F, Hassan C, Kahi CJ et al.. AGA Living Clinical Practice Guideline on Computer-Aided Detection-Assisted Colonoscopy. Gastroenterology 2025. link 26 Ngamruengphong S, Othman MO, Wang AY, Yang D. AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary. Gastroenterology 2025. link 27 Foroutan F, Vandvik PO, Helsingen LM, Kalager M, Rutter M, Selby K et al.. Computer aided detection and diagnosis of polyps in adult patients undergoing colonoscopy: a living clinical practice guideline. BMJ (Clinical research ed.) 2025. link 28 Shaukat A, Ladabaum U, Kanth P, Lieberman D. AGA Clinical Practice Update on Current Role of Blood Tests for Colorectal Cancer Screening: Commentary. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025. link 29 Thomas DE, Horvat N, Fowler KJ, Birkholz JH, Cash BD, Dane B et al.. ACR Appropriateness Criteria® Colorectal Cancer Screening: 2024 Update. Journal of the American College of Radiology : JACR 2025. link 30 Gao C, Chen M, Tong YX, Zhu L, Zhang S. Unlocking the fat factor: How adiposity shapes survival in colorectal cancer-A comprehensive meta-analysis. Clinical nutrition ESPEN 2025. link 31 Socha J, Michalski W, Glynne-Jones R, Glimelius B, Bujko K. Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies. Cancer treatment reviews 2025. link 32 Bretthauer M, Ahmed J, Antonelli G, Beaumont H, Beg S, Benson A et al.. Use of computer-assisted detection (CADe) colonoscopy in colorectal cancer screening and surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2025. link 33 Kinugasa Y, Uehara K, Yamaguchi K, Saito Y, Murofushi K, Sugai T et al.. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer. International journal of clinical oncology 2025. link 34 Li SQ, Wang L, Liu XY, Liu XR, Xie LY. Impact of cardiovascular disease on colorectal cancer morbidity and prognosis. BMC cancer 2025. link 35 Cintosun A, Jamal I, Samnani S, Song YN, Bretthauer M. Gastroenterology/Hepatology: What You May Have Missed in 2024. Annals of internal medicine 2025. link 36 Kay CL, Bader GA, Miller CB. Traditional and Novel Colonoscopy Quality Metrics: What's Important in 2025. Current gastroenterology reports 2025. link 37 Dierick N, Lee C, Kostalas SN. Benchmarking sessile serrated lesion detection in colonoscopy: individual endoscopist performance has greater impact than specialty training - a retrospective analysis of 12,064 procedures. BMC gastroenterology 2025. link 38 Strambi S, Giudice F, Cremonini C, Arces F, Vagelli F, Coccolini F et al.. Is colonic lavage an effective tool for left-sided colonic oncological emergencies?. BMC surgery 2025. link 39 Habermann A, Lee L, Martey S, Siddiqui A, Ranson S, Sharp S et al.. Local and National Trends in Emergency Presentation of Colon and Rectal Cancer. Journal of surgical oncology 2025. link 40 Sciberras P, Paris P, Montebello G, Calleja R, Bugeja R, Camilleri-Brennan J. Predictors of advanced stage and emergency presentation in colorectal cancer patients in central Scotland: A retrospective cohort study. Scottish medical journal 2025. link 41 Banks J, Rashid A, Wilson TR, Challand CP, Lee MJ. Process and outcome differences in the care of patients undergoing elective and emergency right hemicolectomy. Annals of the Royal College of Surgeons of England 2025. link 42 Mihailescu AA, Gradinaru S, Kraft A, Blendea CD, Capitanu BS, Neagu SI. Enhanced rehabilitation after surgery: principles in the treatment of emergency complicated colorectal cancers - a narrative review. Journal of medicine and life 2025. link 43 Orbach L, Gabay S, Montekio T, Chai AS, Kariv Y, Zemel M et al.. Comparison of perioperative outcomes of emergency hartmann resections performed by residents versus attending surgeons. American journal of surgery 2025. link 44 Kudou K, Kajiwara S, Motomura T, Yukaya T, Nakanoko T, Kuroda Y et al.. Novel prognostic score for colorectal necrosis requiring emergency surgery. Surgery today 2025. link 45 Kim HH, Hwang S, Cho J. Prognostic determinants in surgical critial patients undergoing emergency surgery for Stage III or higher colorectal cancer. Langenbeck's archives of surgery 2025. link 46 Somuncu E, Aydın MO, Telci H, Şahin F, Bozdağ E, Yılmaz S et al.. Impact of emergency presentation on early surgical and oncological outcomes in rectosigmoid cancer: a single-center retrospective analysis. Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES 2025. link 47 Aderibigbe AS, Dare AJ, Kalvin HL, Olasehinde O, Wuraola F, Adisa A et al.. Analysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria. Journal of surgical oncology 2025. link 48 Hanafusa M, Nawa N, Ota M, Nakaya T, Fujisaka Y, Fushimi K et al.. Socioeconomic disparities in colorectal cancer oncologic emergencies: a nationwide multilevel analysis in Japan. International journal of clinical oncology 2025. link 49 Jin Z, Jin X, Lu J. Comparative Study on the Efficacy and Safety of Emergency Surgery Versus Endoscopic Stent Placement Followed by Definitive Surgery in the Treatment of Colorectal Obstruction. Annali italiani di chirurgia 2025. link 50 Chen E, Chen L, Zhang W, Zhou W. Self-expanding metal stent as a bridge to elective surgery versus immediate emergency surgery in left-sided obstructive colorectal cancer: a retrospective comparative study. Updates in surgery 2025. link 51 Cutinha FP, Kamath SS, Sunil BV. Intravenous Lignocaine as an Adjunct to Propofol Based Sedation in Colonoscopy: A Prospective, Observational Study. Annals of African medicine 2025. link 52 Ali N, Akbar R, Saleem A, Ali A, Ali A. AI based natural inhibitor targeting RPS20 for colorectal cancer treatment using integrated computational approaches. Scientific reports 2025. link 53 Mortell G, Wooldrage K, Murphy GA, Cross AJ. Changes in faecal haemoglobin values over sequential rounds of faecal immunochemical tests (FIT) in a surveillance population. BMJ open gastroenterology 2025. link 54 Toes-Zoutendijk E, van de Schootbrugge-Vandermeer HJ, Katsara MA, de Jonge L, Spaander MCW, van Vuuren AJ et al.. Harm-to-Benefit Ratio of Fecal Immunochemical Test-Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025. link 55 Karimzadeh F, Heidari R, Lamooki FM, Soureshjani EH, Aziz S, Mirzaei SA. Design of a multi-epitope vaccine against intestinal parasites associated with colorectal cancer using immunoinformatics approaches. Scientific reports 2025. link 56 Young GP, Benton SC, Bresalier RS, Chiu HM, Dekker E, Fraser CG et al.. Fecal Immunochemical Test Positivity Thresholds: An International Survey of Population-Based Screening Programs. Digestive diseases and sciences 2025. link 57 Hyder CS, Uddin MA, Jalal MT, Karim SS, Taher MA, Nahar K et al.. Frequency and Pattern of Premalignant and Malignant Lesions among Fecal Immunochemical Test Positive Patients. Mymensingh medical journal : MMJ 2025. link 58 Zhou Y, Li N, Luo J, Chen Y, Zhang Y, Dai M et al.. Participation and Yield in Multiple Rounds of Colorectal Cancer Screening Based on Fecal Immunochemical Test: A Systematic Review and Meta-Analysis. The American journal of gastroenterology 2025. link 59 Castells A, Quintero E, Bujanda L, Castán-Cameo S, Cubiella J, Díaz-Tasende J et al.. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. Lancet (London, England) 2025. link00145-X) 60 Adhikari K, Mughal MK, Whitworth J, Hignell D, Moysey B, Chishtie J et al.. Evaluating the implementation of a multicomponent intervention to improve faecal immunochemical test-based (FIT) colorectal cancer screening in primary care. BMJ open quality 2025. link 61 Kawamura T, Oda Y, Toyoizumi H, Kato M, Sekiguchi M, Takamaru H et al.. Risk of colorectal cancer among fecal immunochemical test-positive individuals by timing of previous colonoscopy: A multicenter analysis. Journal of gastroenterology and hepatology 2025. link 62 Bhattacharya M, Sarkar A, Wen ZH, Wu YJ, Chakraborty C. Rational Design of a Multi-epitope Vaccine Using Neoantigen Against Colorectal Cancer Through Structural Immunoinformatics and ML-Enabled Simulation Approach. Molecular biotechnology 2025. link 63 Randel KR, Botteri E, de Lange T, Schult AL, Eskeland SL, El-Safadi B et al.. Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds. Alimentary pharmacology & therapeutics 2025. link 64 Gerrard AD, Maeda Y, Noble C, Gunn F, Porteous L, Cheesbrough R et al.. Clinical impact of double-faecal immunochemical testing following implementation into standard triage and investigation of primary care referrals in patients with lower gastrointestinal symptoms. BJS open 2025. link 65 Xu J, Chen S, Niu H, Zhao Y, Wu X, Li Y et al.. Diagnostic accuracy evaluation of individual or combinational fecal immunochemical test, M3 gene, KRAS mutation and tumor methylation burden in colorectal carcinoma. Frontiers in immunology 2025. link 66 Nguyen CM, Yeh PG, Nguyen MP, Johnson TS, Koo H, Champion VL et al.. Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer. Cancer research communications 2025. link 67 Schellack SK, Breidenbach C, Kowalski C, Wedding U, van Oorschot B, Seufferlein T et al.. Pain and overall quality of life in palliatively treated colorectal cancer patients 1 year after diagnosis- results from the EDIUM cohort. Journal of cancer research and clinical oncology 2025. link 68 Mao KL, Jin LY, Chen GQ, Xie J, Chen P, Sun HY et al.. Postmarketing safety signals of cetuximab and panitumumab in the FAERS database: Real-World insights focus on population heterogeneity. European journal of pharmacology 2025. link 69 Xu Y, Wang D, Xu Y. A Real-World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System (FAERS) Database. Cancer medicine 2025. link 70 Lundbech M, Krag AE, Iversen LH, Brandsborg B, Madsen N, Hvas AM. Elevated Thrombin Generation and Venous Thromboembolism Incidence in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Compared with Minimally Invasive Rectal Surgery. Thrombosis and haemostasis 2025. link 71 Ichita C, Goto T, Fushimi K, Shimizu S. Timing of Direct Oral Anticoagulants Resumption Following Colorectal Endoscopic Submucosal Dissection: A Nationwide Study in Japan. The American journal of gastroenterology 2025. link 72 Li D, Ji X, Du X, Zhang Y, Wang Z. A Patient With Rectal Cancer With Cranial Metastasis Resulting in Epidural Hematoma. The Journal of craniofacial surgery 2025. link 73 Donahue CA, Brinton DL, Booth AT, Westfal ML, George V, Maxwell PJ et al.. Guideline-Concordant Extended Pharmacologic Venous Thromboembolism Prophylaxis Utilization After Colorectal Cancer Resection Is Low Regardless of Patient Factors or Hospital Characteristics. Diseases of the colon and rectum 2025. link 74 Raza H, Javaid M, Rehman W, Rafiq S, Rashid Z, Shamim R et al.. Investigation of 5-fluorouracil cardiotoxicity in combinational therapy: Influence of risk factors and demographics in a Pakistani population. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2025. link 75 Siddiqi AK, Shahzad M, Maniya MT, Chachar MA, Saleem N, Garcia M et al.. Shifting trends and disparities in colorectal cancer and heart failure-related mortality in the United States: A two-decade retrospective analysis. Current problems in cardiology 2025. link 76 Dai C, Wang L, Deng Y, Gao X, Zhang J. LDA-SCGB: inferring lncRNA-disease associations based on condensed gradient boosting. BMC bioinformatics 2025. link 77 Nieves-Alonso JM, Gómez Arredondo LA, Maestre Serantes P, Martín Martín C, Guitart de la Lastra F, Ramasco Rueda F. Factors associated with postoperative anastomotic leak and comparison of 4 prediction scales in colorectal surgery. Revista espanola de anestesiologia y reanimacion 2025. link 78 Rezazadeh M, Agah S, Kamyabi A, Ghamkhari Pisheh R, Eshraghi A, Tabaeian SP et al.. Impact of hypertension and angiotensin receptor blockers on colorectal cancer: A retrospective study. Medicine 2025. link 79 Everatt R, Kuzmickienė I, Brasiūnienė B, Vincerževskienė I, Intaitė B, Cicėnas S et al.. Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension. BMC cancer 2025. link 80 Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK et al.. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2024. link 81 Ness RM, Llor X, Abbass MA, Bishu S, Chen CT, Cooper G et al.. NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024. Journal of the National Comprehensive Cancer Network : JNCCN 2024. link 82 Zuo S, Huang Y, Zou J. The role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer. IUBMB life 2024. link 83 Sinha A, Griffith L, Acharjee A. Systematic Review and Meta-Analysis: Taurine and Its Association With Colorectal Carcinoma. Cancer medicine 2024. link 84 Chen J, Ren X, Wang Y, Liu C, Shi S, Sun B. Birth characteristics and risk of colorectal cancer. BMC gastroenterology 2024. link 85 Caruso D, Polici M, Bellini D, Laghi A. ESR Essentials: Imaging in colorectal cancer-practice recommendations by ESGAR. European radiology 2024. link 86 Pericay C, Montagut C, Reina JJ, Melian M, Alcaide J, Tarazona N et al.. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024. link 87 Lugnier C, Sommerlatte S, Attenberger U, Beer AJ, Bentz M, Benz SR et al.. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. Oncology research and treatment 2024. link 88 Albillos A, Carballo F, Crespo J. Strategic analysis and recommendations of the Sociedad Española de Patología Digestiva (SEPD) regarding population-based screening programs for colorectal cancer in Spain. Revista espanola de enfermedades digestivas 2024. link 89 Shi X, Zhao X, Xue J, Jia E. Extracellular vesicle biomarkers in circulation for colorectal cancer detection: a systematic review and meta-analysis. BMC cancer 2024. link 90 Ammirati CA, Passera R, Beltrami E, Peluso C, Francis N, Arezzo A. Laparoscopic and robotic surgery for colorectal cancer in older patients: a systematic review and meta-analysis. Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy 2024. link 91 Nguyen TAVT, Wong SL, Ng ZQ. Surgical resection of adrenal metastasis from colorectal cancers: a systematic review. ANZ journal of surgery 2024. link 92 Wong W. The polarizing nature of fructose. Science signaling 2024. link 93 Gharib E. Closing Editorial: Colorectal Cancer-A Molecular Genetics Perspective. International journal of molecular sciences 2024. link 94 Wright MA, Shibata D. Addressing the Growing Challenge of Young-Onset Colorectal Cancer: The Importance of an Integrated Multidisciplinary Approach. JCO oncology practice 2024. link 95 Gu H. Q&A with Hao Gu. Cell reports 2024. link 96 Sullivan J, Donohue A, Brown S. Colorectal Oncologic Emergencies: Recognition, Management, and Outcomes. The Surgical clinics of North America 2024. link 97 Grenon NN. Colorectal Cancer in Young Adults: Considerations for Oncology Nurses. Clinical journal of oncology nursing 2024. link 98 Luan WY, Lin H, Miao YD. Recommendations for articles and reviews in colorectal cancer-related research at the year-end of 2023. World journal of gastroenterology 2024. link 99 Liu Y, Chen W, Yang R, Zeng X, Zhang J. Effect of serum uric acid and gout on the incidence of colorectal cancer: A meta-analysis. The American journal of the medical sciences 2024. link 100 Yazıcı H, Esmer AC, Vila F, Yeğen C. The Long-Term Prognostic Outcomes of Emergent Colon Cancer Surgery: A Single-Center Experience. Annali italiani di chirurgia 2024. link

Original source

[1]
When the World Stopped: A Lesson in Strength and Second Chances. — Leyfam YL Oncology (Williston Park, N.Y.) (2026)
[2]
Impact of artificial intelligence-assisted colonoscopy on gastroenterology fellow performance: a pragmatic randomized controlled trial. — Chang PW, Nguyen DD, Kong N, Wang D, Wang S, Ong J et al. Gastrointestinal endoscopy (2026)
[3]
Emergency presentation of colorectal cancer in Africa: a scoping review. — Chinyowa S, Murewanhema G, Katsidzira L, Moodley J, Chirenje M, Muguti G BMJ open (2026)
[4]
Understanding the relationship between surgical specialisation and outcomes following emergency surgery for colorectal cancer - a retrospective population-based study in the English NHS. — Birch RJ, Taylor JC, Downing A, Burr NE, Finan P, Quirke P et al. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026)
[5]
Comparative Outcomes of Colorectal Cancer Patients Undergoing Elective and Emergency Surgeries: A Propensity Score Matched Cohort Study. — Kedareswar, Abhinaya RP, Nr VP, Sr A, M R, Jain A et al. Journal of gastrointestinal cancer (2026)
[6]
Performance comparison of quantitative and qualitative fecal immunochemical tests in community-based colorectal cancer screening. — Zhang X, Dou J, Gong Y, Wu C, Pang Y, Wu M et al. Gastrointestinal endoscopy (2026)
[7]
Two-sample fecal immunochemical testing as a tool to avert colonoscopy in symptomatic patients: a prospective multicenter cohort study. — Moen S, Wisse PHA, Marijnissen F, Raab H, Lansdorp-Vogelaar I, Jansen JM et al. Endoscopy (2026)
[8]
Post-marketing signal detection of fruquintinib-associated adverse events using the FAERS database. — Liu C, Zhang H Medicine (2026)
[9]
Photoacoustic Microscopy Imaging and Region-Specific Segmentation of Ileocecal Malignant Tumor and Mixed Hemorrhoid Tissue Sections. — Wang X, Cai M, Mu R, Liu C, Han Y, Xie Z et al. Journal of biophotonics (2026)
[10]
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for preventing colorectal cancer and colorectal adenoma in the general population. — Cai Z, Meng Y, Yang W, Han Y, Cao D, Zhang B The Cochrane database of systematic reviews (2026)
[11]
A case of dramatic response to pembrolizumab monotherapy in dMMR unresectable colorectal cancer diagnosed following abdominal hemorrhage due to segmental arterial mediolysis. — Matsumoto T, Yamashita K, Yumoto S, Ofuchi T, Yamada R, Uemura S et al. Clinical journal of gastroenterology (2026)
[12]
Exploring the nexus: Clinical and physiological correlation between cardiovascular disease and colorectal cancer. — Bashir M, Murtada A, Jubouri M, Awad W, Williams I, Bailey DM Experimental physiology (2026)
[13]
Multicenter clinical validation of a novel rapid single-integrated TAT immunoassay and combined thrombosis biomarker panel for venous thromboembolism risk stratification in colorectal cancer. — Liu M, Guo C, Zhou H, Xie Z, Yang Y, Jin K et al. Clinica chimica acta; international journal of clinical chemistry (2026)
[14]
Absolute quantitative proteomics identifies patterns of plasma proteins associated with venous thromboembolism in patients with colorectal cancer. — Buijs JT, van Es N, Englisch C, Anijs RJS, Bosch FTM, van Vlijmen BJM et al. Thrombosis research (2026)
[15]
Extended thromboprophylaxis in enhanced recovery after surgery for colorectal cancer: a multicentre retrospective cohort study. — Glazemakers ST, Ketelaers SHJ, Cornelisse HB, de Wit F, Pereboom ITA, van der Sluis G et al. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026)
[16]
Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM. — Majano Díaz L, Rodríguez de Santiago E, Núñez Rodríguez H, Corte DP, de Jorge Turrión MÁ, Pellisé M et al. BMJ open (2026)
[17]
Ideal Cardiovascular Health in Colorectal Cancer Patients at Diagnosis. — Romero-Elías M, Álvarez-Bustos A, Gutierrez L, Sánchez Ruiz A, Méndez-Otero M, Fiuza-Luces C et al. Clinical colorectal cancer (2026)
[18]
Evolving biomarkers and risk prediction models in colorectal cancer-associated venous thromboembolism. — Sun L, Wang J, Yan YD, Li LT, Cao LY, Li RF et al. Thrombosis research (2026)
[19]
Cardiovascular health assessed by Life's Essential 8 score, genetic risk, colonoscopy status, and risk of colorectal cancer: an analysis of UK Biobank. — Qiu C, Wang M, Lin S, Zhong Y, Fan M, Chen H et al. BMJ open gastroenterology (2026)
[20]
Enhanced recovery after surgery nursing improves blood pressure stability and reduces complications in hypertensive patients undergoing laparoscopic colorectal resection. — Xia L, Chi Y Medicine (2026)
[21]
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update. — Wang F, Chen G, Zhang Z, Yuan Y, Wang Y, Gao YH et al. Cancer communications (London, England) (2025)
[22]
ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases. — Wach MM, Dineen SP Annals of surgical oncology (2025)
[23]
Glutamine prevents diarrhea in colorectal cancer patients undergoing chemotherapy or chemoradiotherapy: a meta-analysis. — Chen L, Wang D, Meng C, Sun H, Li R, Miao G et al. BMC gastroenterology (2025)
[24]
Multimodal treatment improves survival in patients with lung metastases from colorectal cancer: A network meta-analysis. — Chierici A, Vinci D, Liddo G, Granieri S, Loi M, Alifano M et al. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2025)
[25]
AGA Living Clinical Practice Guideline on Computer-Aided Detection-Assisted Colonoscopy. — Sultan S, Shung DL, Kolb JM, Foroutan F, Hassan C, Kahi CJ et al. Gastroenterology (2025)
[26]
AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary. — Ngamruengphong S, Othman MO, Wang AY, Yang D Gastroenterology (2025)
[27]
Computer aided detection and diagnosis of polyps in adult patients undergoing colonoscopy: a living clinical practice guideline. — Foroutan F, Vandvik PO, Helsingen LM, Kalager M, Rutter M, Selby K et al. BMJ (Clinical research ed.) (2025)
[28]
AGA Clinical Practice Update on Current Role of Blood Tests for Colorectal Cancer Screening: Commentary. — Shaukat A, Ladabaum U, Kanth P, Lieberman D Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025)
[29]
ACR Appropriateness Criteria® Colorectal Cancer Screening: 2024 Update. — Thomas DE, Horvat N, Fowler KJ, Birkholz JH, Cash BD, Dane B et al. Journal of the American College of Radiology : JACR (2025)
[30]
Unlocking the fat factor: How adiposity shapes survival in colorectal cancer-A comprehensive meta-analysis. — Gao C, Chen M, Tong YX, Zhu L, Zhang S Clinical nutrition ESPEN (2025)
[31]
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies. — Socha J, Michalski W, Glynne-Jones R, Glimelius B, Bujko K Cancer treatment reviews (2025)
[32]
Use of computer-assisted detection (CADe) colonoscopy in colorectal cancer screening and surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. — Bretthauer M, Ahmed J, Antonelli G, Beaumont H, Beg S, Benson A et al. Endoscopy (2025)
[33]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer. — Kinugasa Y, Uehara K, Yamaguchi K, Saito Y, Murofushi K, Sugai T et al. International journal of clinical oncology (2025)
[34]
Impact of cardiovascular disease on colorectal cancer morbidity and prognosis. — Li SQ, Wang L, Liu XY, Liu XR, Xie LY BMC cancer (2025)
[35]
Gastroenterology/Hepatology: What You May Have Missed in 2024. — Cintosun A, Jamal I, Samnani S, Song YN, Bretthauer M Annals of internal medicine (2025)
[36]
Traditional and Novel Colonoscopy Quality Metrics: What's Important in 2025. — Kay CL, Bader GA, Miller CB Current gastroenterology reports (2025)
[37]
Benchmarking sessile serrated lesion detection in colonoscopy: individual endoscopist performance has greater impact than specialty training - a retrospective analysis of 12,064 procedures. — Dierick N, Lee C, Kostalas SN BMC gastroenterology (2025)
[38]
Is colonic lavage an effective tool for left-sided colonic oncological emergencies? — Strambi S, Giudice F, Cremonini C, Arces F, Vagelli F, Coccolini F et al. BMC surgery (2025)
[39]
Local and National Trends in Emergency Presentation of Colon and Rectal Cancer. — Habermann A, Lee L, Martey S, Siddiqui A, Ranson S, Sharp S et al. Journal of surgical oncology (2025)
[40]
Predictors of advanced stage and emergency presentation in colorectal cancer patients in central Scotland: A retrospective cohort study. — Sciberras P, Paris P, Montebello G, Calleja R, Bugeja R, Camilleri-Brennan J Scottish medical journal (2025)
[41]
Process and outcome differences in the care of patients undergoing elective and emergency right hemicolectomy. — Banks J, Rashid A, Wilson TR, Challand CP, Lee MJ Annals of the Royal College of Surgeons of England (2025)
[42]
Enhanced rehabilitation after surgery: principles in the treatment of emergency complicated colorectal cancers - a narrative review. — Mihailescu AA, Gradinaru S, Kraft A, Blendea CD, Capitanu BS, Neagu SI Journal of medicine and life (2025)
[43]
Comparison of perioperative outcomes of emergency hartmann resections performed by residents versus attending surgeons. — Orbach L, Gabay S, Montekio T, Chai AS, Kariv Y, Zemel M et al. American journal of surgery (2025)
[44]
Novel prognostic score for colorectal necrosis requiring emergency surgery. — Kudou K, Kajiwara S, Motomura T, Yukaya T, Nakanoko T, Kuroda Y et al. Surgery today (2025)
[45]
Prognostic determinants in surgical critial patients undergoing emergency surgery for Stage III or higher colorectal cancer. — Kim HH, Hwang S, Cho J Langenbeck's archives of surgery (2025)
[46]
Impact of emergency presentation on early surgical and oncological outcomes in rectosigmoid cancer: a single-center retrospective analysis. — Somuncu E, Aydın MO, Telci H, Şahin F, Bozdağ E, Yılmaz S et al. Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES (2025)
[47]
Analysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria. — Aderibigbe AS, Dare AJ, Kalvin HL, Olasehinde O, Wuraola F, Adisa A et al. Journal of surgical oncology (2025)
[48]
Socioeconomic disparities in colorectal cancer oncologic emergencies: a nationwide multilevel analysis in Japan. — Hanafusa M, Nawa N, Ota M, Nakaya T, Fujisaka Y, Fushimi K et al. International journal of clinical oncology (2025)
[49]
Comparative Study on the Efficacy and Safety of Emergency Surgery Versus Endoscopic Stent Placement Followed by Definitive Surgery in the Treatment of Colorectal Obstruction. — Jin Z, Jin X, Lu J Annali italiani di chirurgia (2025)
[50]
Self-expanding metal stent as a bridge to elective surgery versus immediate emergency surgery in left-sided obstructive colorectal cancer: a retrospective comparative study. — Chen E, Chen L, Zhang W, Zhou W Updates in surgery (2025)
[51]
Intravenous Lignocaine as an Adjunct to Propofol Based Sedation in Colonoscopy: A Prospective, Observational Study. — Cutinha FP, Kamath SS, Sunil BV Annals of African medicine (2025)
[52]
AI based natural inhibitor targeting RPS20 for colorectal cancer treatment using integrated computational approaches. — Ali N, Akbar R, Saleem A, Ali A, Ali A Scientific reports (2025)
[53]
Changes in faecal haemoglobin values over sequential rounds of faecal immunochemical tests (FIT) in a surveillance population. — Mortell G, Wooldrage K, Murphy GA, Cross AJ BMJ open gastroenterology (2025)
[54]
Harm-to-Benefit Ratio of Fecal Immunochemical Test-Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations. — Toes-Zoutendijk E, van de Schootbrugge-Vandermeer HJ, Katsara MA, de Jonge L, Spaander MCW, van Vuuren AJ et al. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025)
[55]
Design of a multi-epitope vaccine against intestinal parasites associated with colorectal cancer using immunoinformatics approaches. — Karimzadeh F, Heidari R, Lamooki FM, Soureshjani EH, Aziz S, Mirzaei SA Scientific reports (2025)
[56]
Fecal Immunochemical Test Positivity Thresholds: An International Survey of Population-Based Screening Programs. — Young GP, Benton SC, Bresalier RS, Chiu HM, Dekker E, Fraser CG et al. Digestive diseases and sciences (2025)
[57]
Frequency and Pattern of Premalignant and Malignant Lesions among Fecal Immunochemical Test Positive Patients. — Hyder CS, Uddin MA, Jalal MT, Karim SS, Taher MA, Nahar K et al. Mymensingh medical journal : MMJ (2025)
[58]
Participation and Yield in Multiple Rounds of Colorectal Cancer Screening Based on Fecal Immunochemical Test: A Systematic Review and Meta-Analysis. — Zhou Y, Li N, Luo J, Chen Y, Zhang Y, Dai M et al. The American journal of gastroenterology (2025)
[59]
Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. — Castells A, Quintero E, Bujanda L, Castán-Cameo S, Cubiella J, Díaz-Tasende J et al. Lancet (London, England) (2025)
[60]
Evaluating the implementation of a multicomponent intervention to improve faecal immunochemical test-based (FIT) colorectal cancer screening in primary care. — Adhikari K, Mughal MK, Whitworth J, Hignell D, Moysey B, Chishtie J et al. BMJ open quality (2025)
[61]
Risk of colorectal cancer among fecal immunochemical test-positive individuals by timing of previous colonoscopy: A multicenter analysis. — Kawamura T, Oda Y, Toyoizumi H, Kato M, Sekiguchi M, Takamaru H et al. Journal of gastroenterology and hepatology (2025)
[62]
Rational Design of a Multi-epitope Vaccine Using Neoantigen Against Colorectal Cancer Through Structural Immunoinformatics and ML-Enabled Simulation Approach. — Bhattacharya M, Sarkar A, Wen ZH, Wu YJ, Chakraborty C Molecular biotechnology (2025)
[63]
Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds. — Randel KR, Botteri E, de Lange T, Schult AL, Eskeland SL, El-Safadi B et al. Alimentary pharmacology & therapeutics (2025)
[64]
Clinical impact of double-faecal immunochemical testing following implementation into standard triage and investigation of primary care referrals in patients with lower gastrointestinal symptoms. — Gerrard AD, Maeda Y, Noble C, Gunn F, Porteous L, Cheesbrough R et al. BJS open (2025)
[65]
Diagnostic accuracy evaluation of individual or combinational fecal immunochemical test, M3 gene, KRAS mutation and tumor methylation burden in colorectal carcinoma. — Xu J, Chen S, Niu H, Zhao Y, Wu X, Li Y et al. Frontiers in immunology (2025)
[66]
Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer. — Nguyen CM, Yeh PG, Nguyen MP, Johnson TS, Koo H, Champion VL et al. Cancer research communications (2025)
[67]
Pain and overall quality of life in palliatively treated colorectal cancer patients 1 year after diagnosis- results from the EDIUM cohort. — Schellack SK, Breidenbach C, Kowalski C, Wedding U, van Oorschot B, Seufferlein T et al. Journal of cancer research and clinical oncology (2025)
[68]
Postmarketing safety signals of cetuximab and panitumumab in the FAERS database: Real-World insights focus on population heterogeneity. — Mao KL, Jin LY, Chen GQ, Xie J, Chen P, Sun HY et al. European journal of pharmacology (2025)
[69]
A Real-World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System (FAERS) Database. — Xu Y, Wang D, Xu Y Cancer medicine (2025)
[70]
Elevated Thrombin Generation and Venous Thromboembolism Incidence in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Compared with Minimally Invasive Rectal Surgery. — Lundbech M, Krag AE, Iversen LH, Brandsborg B, Madsen N, Hvas AM Thrombosis and haemostasis (2025)
[71]
Timing of Direct Oral Anticoagulants Resumption Following Colorectal Endoscopic Submucosal Dissection: A Nationwide Study in Japan. — Ichita C, Goto T, Fushimi K, Shimizu S The American journal of gastroenterology (2025)
[72]
A Patient With Rectal Cancer With Cranial Metastasis Resulting in Epidural Hematoma. — Li D, Ji X, Du X, Zhang Y, Wang Z The Journal of craniofacial surgery (2025)
[73]
Guideline-Concordant Extended Pharmacologic Venous Thromboembolism Prophylaxis Utilization After Colorectal Cancer Resection Is Low Regardless of Patient Factors or Hospital Characteristics. — Donahue CA, Brinton DL, Booth AT, Westfal ML, George V, Maxwell PJ et al. Diseases of the colon and rectum (2025)
[74]
Investigation of 5-fluorouracil cardiotoxicity in combinational therapy: Influence of risk factors and demographics in a Pakistani population. — Raza H, Javaid M, Rehman W, Rafiq S, Rashid Z, Shamim R et al. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2025)
[75]
Shifting trends and disparities in colorectal cancer and heart failure-related mortality in the United States: A two-decade retrospective analysis. — Siddiqi AK, Shahzad M, Maniya MT, Chachar MA, Saleem N, Garcia M et al. Current problems in cardiology (2025)
[76]
LDA-SCGB: inferring lncRNA-disease associations based on condensed gradient boosting. — Dai C, Wang L, Deng Y, Gao X, Zhang J BMC bioinformatics (2025)
[77]
Factors associated with postoperative anastomotic leak and comparison of 4 prediction scales in colorectal surgery. — Nieves-Alonso JM, Gómez Arredondo LA, Maestre Serantes P, Martín Martín C, Guitart de la Lastra F, Ramasco Rueda F Revista espanola de anestesiologia y reanimacion (2025)
[78]
Impact of hypertension and angiotensin receptor blockers on colorectal cancer: A retrospective study. — Rezazadeh M, Agah S, Kamyabi A, Ghamkhari Pisheh R, Eshraghi A, Tabaeian SP et al. Medicine (2025)
[79]
Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension. — Everatt R, Kuzmickienė I, Brasiūnienė B, Vincerževskienė I, Intaitė B, Cicėnas S et al. BMC cancer (2025)
[80]
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. — Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK et al. Journal of the National Comprehensive Cancer Network : JNCCN (2024)
[81]
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024. — Ness RM, Llor X, Abbass MA, Bishu S, Chen CT, Cooper G et al. Journal of the National Comprehensive Cancer Network : JNCCN (2024)
[82]
The role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer. — Zuo S, Huang Y, Zou J IUBMB life (2024)
[83]
Systematic Review and Meta-Analysis: Taurine and Its Association With Colorectal Carcinoma. — Sinha A, Griffith L, Acharjee A Cancer medicine (2024)
[84]
Birth characteristics and risk of colorectal cancer. — Chen J, Ren X, Wang Y, Liu C, Shi S, Sun B BMC gastroenterology (2024)
[85]
ESR Essentials: Imaging in colorectal cancer-practice recommendations by ESGAR. — Caruso D, Polici M, Bellini D, Laghi A European radiology (2024)
[86]
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023). — Pericay C, Montagut C, Reina JJ, Melian M, Alcaide J, Tarazona N et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
[87]
Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. — Lugnier C, Sommerlatte S, Attenberger U, Beer AJ, Bentz M, Benz SR et al. Oncology research and treatment (2024)
[88]
Strategic analysis and recommendations of the Sociedad Española de Patología Digestiva (SEPD) regarding population-based screening programs for colorectal cancer in Spain. — Albillos A, Carballo F, Crespo J Revista espanola de enfermedades digestivas (2024)
[89]
Extracellular vesicle biomarkers in circulation for colorectal cancer detection: a systematic review and meta-analysis. — Shi X, Zhao X, Xue J, Jia E BMC cancer (2024)
[90]
Laparoscopic and robotic surgery for colorectal cancer in older patients: a systematic review and meta-analysis. — Ammirati CA, Passera R, Beltrami E, Peluso C, Francis N, Arezzo A Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy (2024)
[91]
Surgical resection of adrenal metastasis from colorectal cancers: a systematic review. — Nguyen TAVT, Wong SL, Ng ZQ ANZ journal of surgery (2024)
[92]
The polarizing nature of fructose. — Wong W Science signaling (2024)
[93]
Closing Editorial: Colorectal Cancer-A Molecular Genetics Perspective. — Gharib E International journal of molecular sciences (2024)
[94]
Addressing the Growing Challenge of Young-Onset Colorectal Cancer: The Importance of an Integrated Multidisciplinary Approach. — Wright MA, Shibata D JCO oncology practice (2024)
[95]
Q&A with Hao Gu. — Gu H Cell reports (2024)
[96]
Colorectal Oncologic Emergencies: Recognition, Management, and Outcomes. — Sullivan J, Donohue A, Brown S The Surgical clinics of North America (2024)
[97]
Colorectal Cancer in Young Adults: Considerations for Oncology Nurses. — Grenon NN Clinical journal of oncology nursing (2024)
[98]
Recommendations for articles and reviews in colorectal cancer-related research at the year-end of 2023. — Luan WY, Lin H, Miao YD World journal of gastroenterology (2024)
[99]
Effect of serum uric acid and gout on the incidence of colorectal cancer: A meta-analysis. — Liu Y, Chen W, Yang R, Zeng X, Zhang J The American journal of the medical sciences (2024)
[100]
The Long-Term Prognostic Outcomes of Emergent Colon Cancer Surgery: A Single-Center Experience. — Yazıcı H, Esmer AC, Vila F, Yeğen C Annali italiani di chirurgia (2024)

Share:Twitter Reddit LinkedIn